Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Mult


This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).


Cellectis, S.A.

Status of enrollment

Accepting new patients

Ages Eligible for Study

Open to adults ages 18 to 64

Genders Eligible for Study

Females and Males

Disease indication

Multiple Myeloma

Principal Investigator

Alfred Chung, MD


Justin Zheng

[email protected]


Additional study eligibility details can be found at UCSF Clinical Trials.